CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to…
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an…
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a…
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…
Reported statistically significant reductions in plasma neurofilament light chain (NfL) levels compared to placebo at…
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
Merger with Notable expected to close in late September or October, subject to VBL’s S-4…
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…
All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot…
On track to begin a Phase 2a trial in the second half of 2023 with…
On track to begin a Phase 2a trial in the second half of 2023 with…
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in…